Promising results as Paradigm repurposes drug for osteoarthritis

As the Australian pharmaceutical sector plans a crackdown on opioid oversupply to consumers, Paradigm Biopharmaceuticals (ASX:PAR) has released its progress results on repurposed thrombotic agent Pentosan Polysulfate Sodium (PPS) for the treatment of degenerative osteoarthritis and bone marrow edema lesions. The injectable therapeutic is often used among athletes with acute knee injuries such as the … Continue reading Promising results as Paradigm repurposes drug for osteoarthritis